Attachment_1_-_Specifications.pdf

1849 C Street, NW – MS 1748, Washington, D.C. 20240 DOI.GOV/IBC

[29APRIL2022]

INDEFINITE

DELIVERY/INDEFINITE

QUANTITY (IDIQ)

COVID-19 TESTING

FOR

U.S. DEPARTMENT OF THE INTERIOR

DOI.GOV/IBC Page i

Contents General Information

Purpose

Objective

Background

Scope

Definitions

Requirements

Vendor Observed COVID-19 Test Requirements

Direct Ship or Bulk Ship (Vendor Observed)

Point-of-Care Testing Facility (Vendor Observed)

Government Observed COVID-19 Test Requirements

Direct Ship or Bulk Ship (Government Observed)

Scope of IDIQ

Ordering / Delivery Requirements

Packaging & Shipments

Ordering / Delivery Examples

Privacy Requirements

Privacy Breach Reporting Requirements

Period of Performance

IDIQ Information, Ordering, & Administration

IDIQ Estimate Requirement

IDIQ Pricing & CLIN Structure

IDIQ Criteria

DOI.GOV/IBC Page ii

IDIQ Administration

Reporting

Order Administration

Procedures for Issuance of Orders

References

DOI.GOV/IBC Page 3

General Information Purpose

The U.S. Department of the Interior (DOI) is seeking testing solutions in response to the COVID-19 pandemic. To ensure DOI can continue its mission and mitigate workplace and community spread of COVID-19, it is critical that appropriate testing solutions are in place to provide detection of COVID-19.

To meet DOI’s COVID-19 testing needs, DOI is considering multiple COVID-19 test types, various observation approaches, and different delivery methods, to include the following:

• COVID-19 Tests:

• Rapid Antigen

• Molecular

• Observations:

• Vendor observed (virtual)

• Vendor observed (Point-of-Care Testing)

• Government observed

• Delivery Methods:

• Bulk shipment to a Government designated location(s)

• Direct shipment to an Employee location

Objective

The objective of the procurement is to provide DOI with an Enterprise-Wide Indefinite Delivery/Indefinite Quantity (IDIQ) for testing solutions in response to the COVID-19 pandemic. To meet this objective, the Interior Business Center’s (IBC) Acquisition Services Directorate (AQD) plans to solicit and award one or more Vendor IDIQ contracts with delegated authority to DOI Bureaus and Offices to issue DOI Bureau or Office specific IDIQ Delivery or Task Orders.

DOI.GOV/IBC Page 4

Background

In response to the COVID-19 pandemic, the U.S. President established the Safer Federal Workforce Taskforce (SFWT) to provide heads of federal agencies ongoing guidance to keep their Employees safe and their agencies operating during the COVID-19 pandemic. Per the SFWT, Federal agencies are required to establish a COVID-19 screening and testing program for its Federal Employees. COVID-19 testing is an effective method for screening asymptomatic individuals for possible COVID-19 infection and diagnostic testing for those who may have encountered exposure to COVID-19 in the workplace, per the Safer Federal Workforce website (https://www.saferfederalworkforce.gov/faq/testing/).

Regarding the requirements established by the SWFT, as well as to ensure federal Employees can support DOI’s mission in a safe workplace environment, DOI is seeking COVID-19 testing solutions to support its COVID-19 testing program. Additionally, given the number of Bureaus and Offices within DOI and their diverse workforce, it is critical DOI’s COVID-19 testing program can afford testing specification flexibility. Specifically, DOI employs approximately 70,000 federal employees in approximately 2,400 locations with offices across the United States, Puerto Rico, U.S. Territories, and Freely Associated States. Listed in Table 1 below is a breakout of DOI’s Bureaus and Offices:

Table 1: U.S. Department of the Interior (DOI) Bureaus and Offices

(Bureaus & Offices | U.S. Department of the Interior (doi.gov))

Bureau / Office Abbreviation

Bureau of Indian Affairs BIA

Bureau of Indian Education BIE

Bureau of Land Management BLM

Bureau of Ocean Energy Management BOEM

Bureau of Reclamation BOR

Bureau of Safety and Environmental Enforcement BSEE

Bureau of Trust Funds Administration BTFA

National Park Service NPS https://www.saferfederalworkforce.gov/faq/testing/ https://www.doi.gov/bureaus

DOI.GOV/IBC Page 5

Office of Surface Mining Reclamation and Enforcements OSMRE

U.S. Fish and Wildlife Services FWS

U.S. Geological Survey USGS

Office of the Secretary OS

Office of Policy, Management, and Budget PMB

Office of the Solicitor SOL

Office of the Inspector General OIG

Office of the Chief Information Officer OCIO

Office of Natural Resources Revenue ONRR

Office of Subsistence Management FWS

Scope

The scope of this requirement is to purchase Rapid Antigen and Molecular tests to detect COVID-19 for DOI Federal Employees that may meet one of the following testing scenarios such as:

• Diagnostic Testing. For DOI Federal Employees who may have experienced a close contact exposure to COVID-19 in the workplace or while performing official duties.

• Ad Hoc Screening Testing. For DOI Federal Employees who require non-recurring screening testing for official travel, official events, and official meetings, or for entry into a facility that requires a negative test prior to entry.

• Routine Screening Testing. For DOI Federal Employees who are unvaccinated, who work onsite or interact in person with members of the public as part of their job duties or for certain DOI Bureau identified roles or functions.

DOI.GOV/IBC Page 6

Definitions

TERM DEFINITION

Bulk Ship Shipping or delivering products to a Government designated facility (single or multiple locations).

COVID-19 An infectious disease often with mild to severe respiratory illness that is caused by coronavirus disease 2019, abbreviated as COVID-19. CO stands for corona, VI for virus, and D for disease. 19 represents the year 2019 that COVID-19 was originally identified.

COVID-19 Testing Kit

A Food and Drug Administration (FDA) or FDA Emergency Use Authorization (EUA) approved or authorized In Vitro Diagnostic (IVD) Rapid Antigen test kit or Molecular test kit that usually involves a nasal swab, saliva swab, or nasopharyngeal swab collection to detect COVID-19. Collection can be self-administered, or point-of-care (POC) administered. Results can either be rapid and displayed in less than 30 minutes or sent to a laboratory for processing.

Direct Ship Shipping or delivering products directly to a Government Employee at their address, such as their home, as identified by the Government.

Emergency Use Authorizations

(EUA)

The Emergency Use Authorization (EAU) authority allows the FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the availability and use of medical countermeasures needed during public health emergencies.

Government Observed

A self-administered COVID-19 test that is virtually or in-person observed by an authorized Government proctor in real-time, not retroactively reviewed.

DOI.GOV/IBC Page 7

In Vitro Diagnostic (IVD) Devices

A test that checks to see if you are infected with COVID-19.

There are 2 types: A Rapid Antigen Test or a Molecular Test.

Molecular Test A type of viral In Vitro Diagnostic (IVD) device test kit that determines if you are infected by analyzing a sample to see if it contains genetic material from the virus (also known as Nucleic Acid Amplification Test (NAAT) or Polymerase Chain Reaction (PCR)). This analysis and test result is performed in a laboratory.

Point-Of-Care Testing Facility

Non-laboratory Facility where In Vitro Diagnostic (IVD) device test kits are performed, such as a pharmacy, drive through, or retail location that operates under a Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver or Certificate of Compliance/Certificate of Accreditation.

Rapid Antigen Test A type of In Vitro Diagnostic (IVD) device test kit that checks to see if you’re currently infected by looking for proteins (antigens) in a sample taken from your nose or throat. This analysis and test result is identified within the test kit.

U.S. Food and Drug Administration

(FDA)

Government agency responsible for reviewing, approving, and regulating medical products.

Vendor Observed A self-administered COVID-19 test that is observed virtually by a telehealth provider, not retroactively reviewed.

Requirements The COVID-19 testing solutions under this IDIQ will be used for DOI Federal Employee personnel that are current, active Federal Civilian Employees accessing a DOI controlled workplace, facility, or controlled land. COVID-19 testing under this IDIQ is not for contractor employees, recipient employees, volunteers, seasonal staff, or official visitors.

The Vendor shall provide COVID-19 testing that includes self-administered testing at a Government facility or Federal Employee’s home residential address with Vendor telehealth

DOI.GOV/IBC Page 8 provider observation when requested; or administered or self-administered testing via Point-of-Care (POC) testing facility.

COVID-19 testing kits provided under this contract vehicle should not expire before 6 months.

An expiration date will be printed on the outer packaging for each unopened and sealed kit.

The expiration date will include the expiration month, day, and year in an easy-to-read format (i.e., Expires after MM/DD/YYYY). The Vendor shall ensure any delivered COVID-19 testing kits will be valid for at least 180 days after delivery. If an expired or damaged test kit product is delivered to the Government, the Vendor shall retrieve and replenish expired or damaged inventory within 3 business days at no expense to the Government.

The Vendor shall store the COVID-19 test kits so they are protected from deterioration by light, moisture, or temperature as directed by the manufacturer.

The Vendor shall comply with the ordering and delivery requirements for COVID-19 test kits as set forth in this IDIQ, to include one-time and reoccurring orders and deliveries.

Vendor Observed COVID-19 Test Requirements

The Vendor shall provide COVID-19 test kits via direct ship, bulk ship, or at a Point of Care (POC) testing facility that involves the Vendor’s direct observation of the administration of the COVID- 19 test kit.

Direct Ship or Bulk Ship (Vendor Observed)

Upon receipt of the shipping information, the Vendor shall:

• Ship the COVID-19 test kits within 7-10 business days, expedited orders shall be shipped within 48 hours

• Include detailed instructions, in layman’s terms, with each COVID-19 test kit for the Employee to coordinate virtually observed testing using a secure portal via an internet connection with the use of a web camera. Instructions must include a Privacy Act Statement (to be provided by the Government to the Vendor). The Government shall be provided an opportunity to review the instructions prior to shipping.

• Minimum requirements for the secure virtual portal include, but are not limited to:

o Must provide video conferencing (visual) with the Employee

DOI.GOV/IBC Page 9 o Must be secure, such that it cannot be accessed by parties who do not have the link o Must have video and audio recording disabled to maintain Employee privacy o Must ensure virtual observation appointments have unique links or access codes, such that an Employee entering the portal cannot accidently join the telehealth visit of another Employee o Must be able to be accessed by Federal Government and individual home computers or other smart devices such as phones with video conferencing o Must not require the download of software to be used o Must be accessible to Doi employees with disabilities and must conform to the Web Content Accessibility Guidelines (WCAG) 2.0 Levels A and AA accessibility standards at a minimum.

• Schedule the virtual testing observation within 3 business days of the Employee request, including instructions in layman’s terms, on performing the sample collection

• Testing observers must be authorized telehealth providers, per the Safer Federal Workforce guidelines

• At observation, confirm the identity of the Employee, monitor and oversee proper sample collection and testing, and provide instructions for receiving results

• The test-specific instructions are as follows:

o Rapid Antigen: view and verbally confirm the test results and provide the test results via secure, encrypted email to the Employee within 30 minutes of the completed sample collection.

o Molecular: provide instructions for shipping the sample to the laboratory.

Each kit shall include postage with tracking and a self-addressed shipping container. The Vendor shall include instructions to the Employee on how to obtain their test results electronically. All vendor instructions must also be available in an accessible electronic format (i.e., Section 508-compliant) for employees with disabilities that use assistive technology. The Employee should receive test results within 2 business days of the laboratory’s receipt of the sample.

DOI.GOV/IBC Page 10

Point-of-Care Testing Facility (Vendor Observed)

The Vendor shall provide and maintain a listing of all eligible Point-of-Care Testing facilities, specifying if it is an in-store or drive-through facility, and ensure the Point-of-Care Testing facilities operates under a Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver or Certificate of Compliance/Certificate of Accreditation. The Vendor shall ensure the list is up to date and provide any changes to the list to the Government Contract Officer Representative (COR) within 10 business days of any change. This list will be used to place orders under this IDIQ.

Upon receipt of the POC order, the Vendor shall:

• Provide detailed instructions to the Employee for scheduling the observed, administered testing

• At testing, confirm the identity of the Employee, oversee proper sample collection, and monitor testing

• Testing observers must be authorized telehealth providers, per the Safer Federal Workforce guidelines

• The telehealth provider shall clearly state the Employee’s COVID-19 test results in person if possible and electronically via secure, encrypted email to the Employee in accordance with the following timelines:

o Rapid Antigen: within 30 minutes of the completed sample collection o Molecular: within 2 business days of the laboratory’s receipt of the sample

• All guidance received from telehealth or health care providers shall align with overarching guidance and direction they have been instructed to give under the larger overall health care provider’s guidance requirements.

Government Observed COVID-19 Test Requirements

The Vendor shall provide COVID-19 test kits via direct ship or bulk ship, without observation.

DOI.GOV/IBC Page 11

Direct Ship or Bulk Ship (Government Observed)

Upon receipt of the shipping information, the Vendor shall:

• Ship the COVID-19 test kits within 7-10 business days, expedited orders should be shipped within 48 hours

• Include detailed instructions on performing the sample collection

The test-specific detailed instructions shall include the following:

• Rapid Antigen: provide details on how to read the results

• Molecular: provide instructions for shipping the sample to the laboratory. Each kit shall include postage with tracking and a self-addressed shipping container. The Vendor shall provide instructions to the Employee on how they will obtain test results. Results must be provided within 2 business days of the laboratory’s receipt of the sample.

Scope of IDIQ

DOI is seeking testing solutions in response to the COVID-19 pandemic over a 12-month period, with up to two 12-month option periods. The Government reserves the right to not exercise all or any optional periods of the IDIQ contract.

Ordering / Delivery Requirements

All deliveries shall be scheduled and coordinated between the Vendor point of contact and the assigned Government COR after award. COVID-19 test kit quantities and delivery methods will be requested based on the DOI Bureau or Office needs and can include a variety of ordering and delivery requirements. Test orders will be ordered and shipped in a quantity of one for Point-Of-Care. Test orders for Employees will be ordered and shipped in a quantity of two or in quantities of six. Test orders for Government Facilities will be ordered and shipped in a quantity of six.

Packaging & Shipments

All deliveries must be packaged and clearly marked with the name of the DOI Bureau or Office and the name of the Government POC or the name of the Employee. The Government COR will

DOI.GOV/IBC Page 12 provide the address of the Government facility and POC receiving shipment or the Employee’s home address to the Vendor. All packing, packaging, and mailing of supplies or materials shall be accomplished in the most economical and efficient manner and in accordance with the best commercial practices. All postage and fees shall be paid by the Vendor. Employees who have opted to receive test kits at their residential address have consented to providing their residential address to a third party for the purpose of receiving the COVID-19 test kit only.

Addresses provided by DOI to the Vendor for use in contract performance may not be used for any other purposes.

Ordering / Delivery Examples

The Government reserves the right to modify the number of test kits, type of test kits, and type of observation testing needed in response to DOI Employee need and testing recommendation updates from the Safer Federal Workplace guidance.

The following are examples of how the orders may be placed:

• A one-time order for one-time shipping to individual Employees.

o Scenario: Order for 12 Rapid Antigen Tests with identification of 2 Employees shipping within 7-10 business days of order:

Employee #1

• Name of Employee

• Employee Address

• Delivery Date & Quantity o Example: March 2022 (QTY 6)

Employee #2

• Name of Employee

• Employee Address

• Delivery Date & Quantity o Example: May 2022 (QTY 6)

• A one-time bulk order to one or more Government facilities, with quantities to ship to each facility address.

o Scenario: Order for 504 Rapid Antigen Tests with identification of 2 Government facilities with shipping as detailed in the order:

Facility #1

• Name of DOI Bureau or Office 1

DOI.GOV/IBC Page 13

• POC Receiving Shipment

• Address

• Delivery Date & Quantity o Example: March 2022 (QTY 252) Facility #2

• Name of DOI Bureau of Office 2

• POC Receiving Shipment

• Address

• Delivery Date & Quantity o Example: May 2022 (QTY 252)

• A cyclical order to repeat on a specified schedule, provided by the COR at time of award, to include the total number of tests, one or more Employee names and a shipping address for each individual Employee.

o Scenario: Order for 72 Rapid Antigen Tests with identification of 2 Employees to receive cyclical shipments shipped every five weeks, with the first shipment within 7-10 business days of order. Information provided will include:

Employee #1

• Name of Employee

• Employee Address

• Quantity and Delivery Date(s) o Example: March 7, 2022 (QTY 12); April 11, 2022 (QTY 12); May 16, 2022 (QTY 12)

Employee #2

• Name of Employee

• Employee Address

• Quantity and Delivery Date(s) o Example: March 7, 2022 (QTY 12); April 11, 2022 (QTY 12); May 16, 2022 (QTY 12)

• A cyclical bulk order to repeat on a specified schedule, provided by the COR at time of award, to include one or more Government facilities and a shipping address(es) for each Government facility, with quantities to ship to each Government facility.

o Scenario: Order for 756 Rapid Antigen Tests with identification of 1 Government Facility to receive cyclical shipments, shipped every four months, with the first shipment within 7-10 business days of order. Information provided will include:

Facility #1

• Name of DOI Bureau or Office 1

• POC Receiving Shipment

DOI.GOV/IBC Page 14

• Address

• Quantity and Delivery Date(s) o Example: March 7, 2022 (QTY 252); July 7, 2022 (QTY 252); November 7, 2022 (QTY 252)

• A quantity order that will be delivered over the entire Period of Performance (PoP) for tests to be shipped directly to the Employee.

o Scenario: Order for 72 Rapid Antigen Tests at time of award. COR will provide a listing monthly of where to ship COVID-19 test kits. Some months none may be shipped, and quantities may vary each month. Tests will be shipped within 7-10 days of receiving the list. Information provided will include:

First list:

• Employee #1:

o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: March 7, 2022 (QTY 12)

• Employee #2:

o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: March 7, 2022 (QTY 12)

• Employee #3:

o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: March 7, 2022 (QTY 12)

• Employee #4:

o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: March 7, 2022 (QTY 12)

Second List:

• Employee #1:

o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: April 11, 2022 (QTY 12)

• Employee #2:

DOI.GOV/IBC Page 15 o Name of Employee o Employee Address o Quantity and Delivery Date(s)

Example: April 11, 2022 (QTY 12)

• A quantity order that will be delivered over the entire PoP for tests to be delivered to a Government facility via mail to include one or more Government facilities.

o Scenario: Order for 1008 Rapid Antigen Tests at time of award. COR will provide a list of where to ship COVID-19 test kits and quantity. Some months none may be shipped, and quantities may vary each month. Tests will be shipped within 7-10 days of receiving the list. Information will include:

First List:

o Facility #1 Name of DOI Bureau or Office 1 POC Receiving Shipment Address Quantity and Delivery Date(s) within PoP

• Example: PoP is April 1, 2022 – March 31, 2023. May 2022 (QTY 168);

December 2022 (QTY 168); February

2023 (QTY 168)

Second List:

o Facility #2 Name of DOI Bureau or Office 2 POC Receiving Shipment Address Quantity and Delivery Date(s) within PoP

• Example: PoP is April 1, 2022 – March 31, 2023. June 2022 (QTY 168);

January 2022 (QTY 168); March 2023

(QTY 168)

Privacy Requirements

COVID-19 testing must be conducted and results must be handled in compliance with all applicable Federal and State privacy laws and regulations to safeguard Personally Identifiable Information (PII). PII means information that can be used to distinguish or trace an individual’s identity, either alone or when combined with other information that is linked or linkable to a

DOI.GOV/IBC Page 16 specific individual. Examples of PII include, but are not limited to, name, mailing address, telephone number, email address, testing participation, status, and test results. The Government and vendor must be able to securely transfer PII such as Federal Government personnel names and addresses. The privacy and confidentiality of Employees’ identities, addresses, and test results must be maintained as provided by law for the collection, handling, processing, and sharing of PII and ensure compliance with the privacy control requirements and standards. PII is a subset of information designated as Controlled Unclassified Information (CUI) that shall be managed in accordance with applicable laws, regulations, executive orders, and policies regarding the safeguarding and dissemination of CUI.

Information systems and system services provided to the DOI by the Contractor must comply with current DOI Information Technology (IT) Cybersecurity and Privacy Control Standards, privacy policies and other related guidance.

Vendor must restrict access to all PII and secure CUI data according to federal guardianship requirements. Vendor is required to comply with current Federal laws, regulations, standards, and guidance found in the Federal Information Security Modernization Act (FISMA), Federal Risk and Authorization Management Program (FedRAMP) for cloud hosted systems, the Privacy Act of 1974, Section 208 of the E-Government Act of 2002, Federal Information Processing Standards (FIPS) and the National Institute of Standards and Technology (NIST) Special Publication 800-53 and other 800-Series Special Publications (SP), Office of Management and Budget (OMB) policy, and other relevant Federal laws and regulations that apply to the collection, maintenance and safeguarding of Federal government information.

Any information collected, maintained, and disclosed pursuant to COVID-19 testing must be collected, maintained, and disclosed in compliance with, as applicable, the Privacy Act of 1974, as amended, 5 U.S.C. § 552a, the Coronavirus Aid, Relief, and Economic Security Act (CARES) Act, Health Insurance Portability and Accountability Act (HIPAA) (when otherwise applicable), and any other applicable law. Employee records shall be maintained as confidential medical records in accordance with the Office of Personnel Management (OPM) regulations and the applicable system of records notices, OPM/GOVT-10, Employee Medical File System Records, 75 Fed. Reg. 35099 (June 21, 2010), amended 80 Fed. Reg. 74815 (Nov. 30, 2015), and INTERIOR/DOI-92, Public Health Emergency Response Records, 86 FR 60900 (Nov. 4, 2021), which govern the maintenance and disclosure of employees’ COVID-19 testing program records. Vendor shall obtain explicit written approval from the Contracting Officer for any release of records from this system and maintain a record of any such authorized disclosures.

DOI.GOV/IBC Page 17

Privacy Breach Reporting Requirements

Vendor must provide notice to DOI Contracting Officer (CO) of any known or suspected breach of PII in electronic or physical form to the CO via email within one hour of discovery and support agency actions to meet breach reporting and mitigation requirements outlined in the DOI Privacy Breach Response Plan and OMB Memorandum M-17-12.

Vendor must provide a detailed written analysis with the following data elements available at the time of the breach:

• Location of breach

• Date and time the breach was discovered

• Nature of the event (loss, theft, unauthorized access)

• Description or summary of events

• Description of PII involved, such as name, address, etc.

• Number of potentially impacted individuals

Period of Performance

The anticipated period of performance will include a 12-month base period and two 12-month optional periods for a total of 36 months.

The Vendor shall complete the work associated with each order in accordance with the completion time specified on the order.

IDIQ Information, Ordering, & Administration IDIQ Estimate Requirement

The Government estimates, but does not guarantee, the volume of purchases using this IDIQ.

As the pandemic evolves and testing requirements continue to change on a frequent basis, it is possible that minimal or no testing orders will be placed under this this vehicle.

The Government is obligated only to the extent of authorized orders executed under the

IDIQ.

DOI.GOV/IBC Page 18

IDIQ Pricing & CLIN Structure

This IDIQ provides the basis for awarding IDIQ contracts to one or more Vendors for COVID- 19 testing. Individual orders will be issued against this IDIQ.

IDIQ Criteria

The resulting IDIQ and resulting orders shall not be for personal services.

IDIQ Administration

The IDIQ and resulting orders are exclusively in support of DOI. Therefore, warranted Contracting Officers (COs) employed by other Federal Agencies are not authorized and will not be delegated to issue orders under this IDIQ.

The CO of record for the resulting IDIQ resides in the IBC, AQD. An IBC AQD CO will be responsible for executing modifications to the master IDIQ order.

All IDIQ questions and concerns will be directed to the Government CO assigned at the IDIQ level. The IDIQ Government CO and Alternate CO are the only individuals with the authority to financially obligate the Government and to make changes to original terms and conditions of this IDIQ.

Table 2: IDIQ Contracting Officer (CO) Information

Contracting Officer (CO) Alternate Contracting Officer (CO)

TBD

Acquisition Services Directorate Interior Business Center Office of the Secretary

U.S. Department of the Interior 381 Elden Street, Suite 4000

Herndon, VA 20170-4817 Phone: (703) 964-XXXX

Cell: XXX-XXX-XXXX

TBD

DOI.GOV/IBC Page 19

E-mail: TBD@ibc.doi.gov

Reporting

The Vendor shall provide monthly reporting to the DOI CO summarizing all orders, to include but limited to:

• Number of orders by Contract Line Item Number (CLIN)

• Expenditures by CLIN

• Any other pertinent reports required by the Government as directed by the CO

Order Administration

Orders will be issued when requirements are identified by the ordering activity at the DOI Bureau or Office level.

Resulting orders are decentralized and will be executed at the Bureau and Office level. The Government CO may authorize an alternate CO as necessary, in writing.

All order questions and concerns will be directed to the Government CO assigned at the order level.

Payment of orders may be completed by the Government purchase card or paid through Government invoicing processes.

Procedures for Issuance of Orders

All work performed under the IDIQ will be specifically identified by the issuance of an order.

All orders are subject to the terms and conditions of the IDIQ. In the event of a conflict between any order and this IDIQ, the IDIQ shall govern.

mailto:TBD@ibc.doi.gov

DOI.GOV/IBC Page 20

References Table 3: IDIQ Reference Links

Topic Link

(1) U.S. Department of the Interior Bureaus & Offices

Bureaus & Offices | U.S. Department of the Interior (doi.gov)

(2) Food and Drug Administration (FDA) Emergency Use Authorization (EUA)

Food and Drug Administration (FDA) Emergency Use Authorization (EUA)

(3) Safer Federal Workforce https://www.saferfederalworkforce.gov/faq/testing https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19euas https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19euas https://www.saferfederalworkforce.gov/faq/testing

References